D. Dubé

发表

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Chun Xing Li, R. Young, S. Charleson, 2005, Bioorganic & medicinal chemistry letters.

The discovery and synthesis of potent zwitterionic inhibitors of renin.

J. Falgueyret, M. Percival, S. Gagné, 2011, Bioorganic & medicinal chemistry letters.

REDUCTIVE N-ALKYLATION OF AMIDES, CARBAMATES AND UREAS

D. Dubé, Andrew A Scholte, D. Dubé, 1999 .

NOVEL 1,2-DIARYLCYCLOBUTENES : SELECTIVE AND ORALLY ACTIVE COX-2 INHIBITORS

D. Riendeau, C. Chan, W. Cromlish, 1996 .

L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.

L. Zhang, R. Young, J. Mancini, 2007, Biochemical pharmacology.

The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.

R. Young, D. Nicholson, Y. Girard, 2010, Bioorganic & medicinal chemistry letters.

Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.

Yongxin Han, S. Gagné, Y. Ducharme, 2011, Bioorganic & medicinal chemistry letters.

3,4-Diarylpiperidines as potent renin inhibitors.

J. Falgueyret, Yongxin Han, E. Cauchon, 2012, Bioorganic & medicinal chemistry letters.

Identification of a new biaryl scaffold generating potent renin inhibitors.

C. Bayly, D. McKay, R. Aspiotis, 2010, Bioorganic & medicinal chemistry letters.

Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.

S. Gagné, D. McKay, E. Grimm, 2010, Bioorganic & medicinal chemistry letters.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

R. Young, J. Mancini, D. Nicholson, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

R. Young, J. Mancini, H. Perrier, 2008, Bioorganic & medicinal chemistry letters.

Dynamic Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Type 3 and Type 4D Phosphodiesterase Inhibitors

M. Tota, A. Veilleux, R. Friesen, 2005, Journal of Pharmacology and Experimental Therapeutics.

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.

R. Young, D. Éthier, J. Mancini, 2003, Bioorganic & medicinal chemistry letters.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.

J. Falgueyret, M. Percival, Yongxin Han, 2011, Bioorganic & medicinal chemistry letters.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.

J. Falgueyret, M. Percival, Yongxin Han, 2011, Bioorganic & medicinal chemistry letters.

Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.

C. Bayly, S. Gagné, S. Soisson, 2010, Bioorganic & medicinal chemistry letters.

Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.

J. Falgueyret, D. Riendeau, R. Young, 1998, Bioorganic & medicinal chemistry letters.

2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors.

D. Riendeau, C. Brideau, C. Chan, 1999, Bioorganic & medicinal chemistry letters.

Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of medicinal chemistry.

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

J. Falgueyret, D. Riendeau, C. Brideau, 1996, Journal of medicinal chemistry.

Studies on the deconjugation−epimerization strategy en route to avermectin B1a: problems and solutions

S. Hanessian, D. Dubé, P. J. Hodges, 1987 .

A novel synthetic route to the hexahydrobenzofuran subunit of the avermectins and milbemycins

P. Beaulieu, S. Hanessian, D. Dubé, 1986 .

Facile access to (S)-1,2,4-butanetriol and its derivatives

S. Hanessian, D. Dubé, A. Ugolini, 1984 .

Synthesis of (+)-avermectin B1a

S. Hanessian, D. Dubé, P. J. Hodges, 1986 .

Synthetic Study toward Total Synthesis of (±)-Germine: Synthesis of (±)-4-Methylenegermine.

A. Clark, P. Parsons, M. Kitamura, 2017, Organic letters.

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

R Gordon, J. Falgueyret, M. Percival, 2001, The Journal of pharmacology and experimental therapeutics.

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.

R Gordon, R Fortin, D. Riendeau, 1998, Bioorganic & medicinal chemistry letters.

Progress in natural product chemistry by the chiron and related approaches - synthesis of avermectin B1a

P. Beaulieu, S. Hanessian, D. Dubé, 1987 .

H(2)D3: a cationic porphyrin designed to intercalate into B-form DNA (H(2)D3 = trans-di(N-methylpyridium-3-yl)porphyrin).

L. Bonaccorsi, D. McMillin, D. Dubé, 2001, Journal of the American Chemical Society.

Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.

H. Perrier, K. Bateman, Y. Girard, 2006, Journal of mass spectrometry : JMS.

Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.

S. Charleson, J. Mancini, H. Perrier, 2006, Bioorganic & medicinal chemistry letters.

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

R. Young, J. Mancini, R. Friesen, 2010, Bioorganic & medicinal chemistry letters.

The controlled degradation of avermectin B1a

S. Hanessian, D. Dubé, P. J. Hodges, 1986 .